McKesson/HBOC has filed a countersuit against shareholders who sued the company after its stock took a nosedive in mid-1999 (HNN 10/18/00). McKesson/HBOC stock lost $9 billion in value in one day after revelation of a financial scandal
McKesson/HBOC has filed a countersuit against shareholders who sued the company after its stock took a nosedive in mid-1999 (HNN 10/18/00). McKesson/HBOC stock lost $9 billion in value in one day after revelation of a financial scandal involving Albert Bergonzi and Jay Gilbertson, co-presidents and co-chief operating officers for HBOC before the merger of McKesson and HBOC.
The two men were indicted in October by the U.S. Securities and Exchange Commission on 17 counts of securities fraud, conspiracy, mail fraud, and wire fraud for falsifying company ledgers to boost HBOC profits prior to the merger in January 1999. When McKesson/HBOC announced in April 1999 that it would have to restate several years' worth of earnings reports, the company's stock fell from around $66 per share to $34.50 in one day. This prompted the shareholder lawsuit.
McKesson/HBOC's countersuit, however, alleges that stockholders were "unjustly enriched" before the stock crash and that the company was victimized as well. While the shareholder complaint claims that McKesson knew about HBOC's financial finagling before finalizing its purchase of HBOC, McKesson denies the charge.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
2 Commerce Drive
Cranbury, NJ 08512